Can Blood Tests Predict ALS Before It Strikes? Here’s What Scientists Found - StudyFinds

What the report says

StudyFinds reports that researchers have identified a 19-protein blood panel that may help forecast the onset of amyotrophic lateral sclerosis, or ALS, in people carrying ALS-linked gene variants. The findings, published in Nature Medicine, suggest the panel could predict whether a participant in the studied groups would develop symptoms within time windows ranging from six months to five years. It also estimated time to symptom onset with an average error of about 1.6 years, compared with about 2.4 years for NEFL, a leading single blood marker.

The study used about 18 years of data from the Pre-Symptomatic Familial ALS study, examining 516 plasma samples from 137 participants, including people who later developed ALS, people already diagnosed, asymptomatic gene carriers and healthy controls. Researchers measured more than 5,400 proteins and found 92 that changed before symptoms appeared. Machine-learning models were then used to identify the protein combination most useful for predicting “phenoconversion,” the shift from gene carrier status to clinical disease.

StudyFinds notes that the panel outperformed NEFL alone across most prediction windows, though NEFL performed similarly in the shortest six-month window. Several proteins in the panel are tied to muscle biology rather than direct nerve damage, raising the possibility that muscle-related changes may begin earlier than previously recognized.

The report emphasizes that the test is not ready for routine medical use. The participant group was relatively small and focused on specific genetic forms of ALS, and the technology used is not a standard clinical lab method. If validated, such a tool could help prevention trials identify people most likely to develop symptoms within a practical study period.